Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.70 |
| ▸ | CES2 | O00748 | 1/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240086 | 0.92 | GSK3B (0.71) | CES1CES2GSK3BHSD11B1TDP1 | |
| SCHEMBL6650467 | 0.89 | GSK3B (0.62) | CES1CES2GSK3BHSD11B1TDP1 | |
| SCHEMBL9207986 | 0.89 | CES1 (0.70) | CES1CES2GSK3BHSD11B1ALOX5 | |
| SCHEMBL522192 | 0.86 | ALDH1A1 (0.64) | CES1CES2GSK3BHSD11B1ALOX5 | |
| SCHEMBL10789142 | 0.85 | GSK3B (0.62) | CES1CES2GSK3BHSD11B1ALOX5 | |
| SCHEMBL9734470 | 0.85 | GSK3B (0.67) | CES1CES2GSK3BHSD11B1TDP1 | |
| SCHEMBL6575965 | 0.85 | CES2 (0.51) | CES1CES2GSK3BHSD11B1ALOX5 | |
| SCHEMBL11756878 | 0.84 | FFAR1 (0.64) | CES1CES2GSK3BHSD11B1TDP1 | |
| SCHEMBL5500374 | 0.84 | TP53 (0.67) | CES1CES2MAPK1ALDH1A1MAPT | |
| SCHEMBL1982760 | 0.84 | GSK3B (0.66) | CES1CES2GSK3BHSD11B1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1848692-A1 | AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS | Wyeth (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088711-A1 | AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | BACE1, BACE2, APP | CES1 600/4885CES2 2049/4885GSK3B 283/4885 |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | BACE1, BACE2, APP | CES1 600/4885CES2 2049/4885GSK3B 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.